Kilitch Drugs (India) Limited (KILITCH) fundamentals
Kilitch Drugs (India) Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as KILITCH (ISIN INE729D01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Kilitch Drugs (India) Limited does
Kilitch Drugs (India) Limited is an India-based pharmaceutical manufacturing company. The Company is mainly engaged in the development and operations of the pharmaceutical business. Its services range from manufacturing to marketing a host of formulations in all dosage forms. The Company offers products in the categories of Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. It offers products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostics, uterine stimulants, veterinary and many more areas in the form of ampoules & vials. Its range of oral formulations includes tablets, capsules, dry syrups and oral powders. It provides a range of cosmetics ranging from oil, lotion, liquid to cream and paste in the skin care, personal care and hair care categories. It offers a medical device, namely, the C-Seal. ROIPAR, ROIVIT, PH-7, C-SEAL, SRO-KIT, 9-VIT, HPURE are their product offerings.
Valuation and market data
| Last close | ₹185.00 |
|---|---|
| Market capitalisation | ₹613 crore |
| Enterprise value | ₹656 crore |
| P/E (TTM) | 20.76 |
| Price to book | 2.21 |
| Price to sales (TTM) | 1.55 |
| Book value per share | ₹83.62 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Sep 29 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹202 crore | ₹42 crore | ₹32 crore | 9.57 |
| Mar 2025 | ₹195 crore | ₹41 crore | ₹31 crore | 19.37 |
| Mar 2024 | ₹138 crore | ₹23 crore | ₹18 crore | 11.03 |
| Mar 2023 | ₹122 crore | ₹19 crore | ₹16 crore | 10.09 |
| Mar 2022 | ₹110 crore | ₹14 crore | ₹11 crore | 6.76 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 63.8% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 36.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.